Counseling Points - December 2008 - (Page 14)

Counseling Points™ Future Treatments for Rheumatoid Arthritis Continuing Education Posttest To receive credit, please read the newsletter in its entirety and answer the posttest and program evaluation questions using the answer key on page 15. This entire program is also available at www.counselingpoints.com. Please mail or fax the form to Delaware Media Group, 66 South Maple Ave., Ridgewood, NJ 07450, Fax (201) 612-8282. (If you are completing the posttest online, simply hit the “submit” button.) A certificate from the Infusion Nurses Society will be awarded for a score of 80% (8 correct) or better. A certificate will be mailed within 4 to 6 weeks.There is no charge for CE credit. 1. Choose the drug that is not a TNF inhibitor. A) Adalimumab B) Certolizumab C) Golimumab D) Ofatumumab 2. The addition of polyethylene glycol to certolizumab: A) increases drug half-life B) decreases drug half-life C) increases rheumatoid factor D) none of the above 3. Choose the golimumab dosing regimen that is currently being studied in clinical trials. A) Oral, daily B) Once-monthly subcutaneous injection C) Intravenously every 3 months D) Both B and C 4. The most common serious adverse event that occurred with golimumab therapy during the GO-FORWARD trial was: A) nausea B) pneumonia C) injection-site swelling D) urinary tract infection 5. Elevated levels of BLyS decrease the body’s potential to produce autoantibodies. A) True B) False 6. Atacicept is being studied alone and in combination with which other drug(s)? A) Atorvastatin B) Golimumab and methotrexate C) Rituximab and adalimumab D) Tacrolimus 7. Choose the statement that is false: A) IL-6 is a pleiotropic and pro-inflammatory cytokine B) IL-6 is found in abnormally high amounts in synovial tissue of RA patients C) IL-6 is responsible for decreases in ESR and CRP D) IL-6 is thought to activate T cells, macrophages, and osteoclasts 8. In the OPTION study, of patients taking tocilizumab 8 mg/kg achieved an ACR20 response at 24 weeks. A) 10% B) 29% C) 59% D) 70% 9. In the OPTION trial, both the tocilizumab 4 mg/kg and 8 mg/kg groups demonstrated: A) decreases in hemoglobin levels B) increases in hemoglobin levels C) no change in hemoglobin levels D) none of the above 10. Choose the group of intercellular molecules responsible for the transfer of phosphate from donor molecules to recipient molecules. A) BLyS B) Cytokines C) Kinases D) None of the above COUNSELING POINTS™ 14 http://www.counselingpoints.com

Table of Contents Feed for the Digital Edition of Counseling Points - December 2008

Counseling Points - December 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.